IGM-2644
Multiple Myeloma
PreclinicalDiscovery/Preclinical
Key Facts
About IGM Biosciences
IGM Biosciences' mission is to harness the unique properties of engineered IgM antibodies to create superior therapeutics for cancer and autoimmune disorders. Its key achievement is the advancement of a bispecific IgM T-cell engager, imvotamab, into multiple Phase 2 trials for B-cell malignancies, alongside other clinical-stage oncology and immunology candidates. The company's strategy is to clinically validate its proprietary IgM platform, demonstrating differentiated efficacy and safety profiles that can support future partnerships or independent commercialization. IGM operates as an R&D-focused public entity, aiming to establish a new class of antibody medicines.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |